Rx to OTC switch requirements and FDA, EU and UK pathways

An Rx to OTC switch changes a prescription drug product to nonprescription availability for specified conditions of use. In the US, FDA must find that prescription requirements are not necessary for the protection of the public health, and that the drug is safe and effective for self-medication as directed in the proposed labeling. Approval does not make every strength, indication or product containing the ingredient OTC. FDA's switch overview makes the distinction at the product level.

For regulatory teams, the starting question is which conditions of use will change. A full switch and a partial switch use different FDA application routes. UK pharmacy supply has separate limits, while EU procedures depend on the marketing authorisation.

FDA full and partial Rx to OTC switches

FDA defines a full switch as changing an NDA drug product's marketing status to nonprescription in its entirety. The sponsor submits an efficacy supplement to an approved new drug application (NDA) or a 505(b)(2) application. A partial switch changes some conditions of use, such as indications, while others remain prescription. That route requires a new NDA. These are FDA's stated route distinctions.

Define the proposed OTC conditions before choosing the application route. Calling the proposal an "OTC switch" does not settle whether it is a full or partial switch.

The legal standard addresses self-medication under the proposed labeling. Under 21 CFR 310.200, prescription requirements must be unnecessary for public-health protection. The drug must also be safe and effective for self-medication as directed in that labeling.

The regulation permits initiation by the Commissioner or an interested person, including through a petition or NDA supplement. But a petition itself does not permit marketing. Those options sit beside the usual sponsor application routes. They do not replace them.

Nor is every OTC approval a prescription-to-OTC switch. FDA distinguishes the drug-application and OTC-monograph pathways, and a product can receive direct-to-nonprescription approval without prior prescription approval. Its nonprescription application overview explains those differences.

What evidence supports nonprescription use?

The application should contain safety and efficacy evidence for the proposed nonprescription conditions. The applicant must also show that consumers can understand safe and effective use without a healthcare professional's supervision, and must provide postmarketing safety-surveillance data. Existing prescription trials and new randomized controlled trials are possible evidence sources. FDA does not say every switch needs new efficacy trials. See its switch evidence requirements.

Consumer studies address different questions. FDA says they are often needed, and its application overview identifies these study types:

• Label-comprehension studies test whether consumers understand labeling and can apply it to a hypothetical use decision.
• Self-selection studies test whether consumers can apply labeling to their own health situation and decide whether the drug suits them.
• Actual-use studies examine use in real-world conditions without healthcare-provider intervention.
• Human-factors studies assess whether the user-interface design reduces use-related hazards.

These studies aren't interchangeable. Understanding a warning in a hypothetical question differs from deciding whether that warning applies to you. Selecting the right product also differs from using it correctly.

Whatever studies are used have to fit the proposed product and conditions of use. FDA's overview does not impose every study category on every switch, or give a universal passing percentage. A generic checklist cannot settle which consumer-use questions the application needs to answer.

ACNU when labeling alone is insufficient

An additional condition for nonprescription use, or ACNU, provides a route where labeling alone is insufficient. Under 21 CFR 314.56, the applicant must demonstrate, and FDA must determine, that labeling alone is insufficient for appropriate self-selection, actual use, or both. The approved additional condition must then achieve appropriate selection or use without practitioner supervision.

Initial ACNU approval requires a separate application, not a supplement. The NDA must explain why the condition is needed, how it operates and its key elements. It must also include consumer-success criteria and supporting evidence. The regulation allows prescription and ACNU nonprescription versions to coexist without another meaningful difference between them.

The rule became effective on May 27, 2025, after delays to the original effective date. The March 25, 2025 Federal Register notice records the final delay. FDA reported no approved ACNU nonprescription drugs in its August 13, 2026 status update.

ACNU does not replace labeling duties. Section 201.67 requires the ACNU labeling statement and addresses misbranding when applicable requirements are unmet or the approved condition is not implemented.

UK reclassification separates pharmacy and general sale

The UK has three legal classifications: prescription-only medicines (POM), pharmacy medicines (P), and general sale medicines (GSL). "OTC" informally covers P and GSL. It is not itself a legal classification, according to MHRA's reclassification guidance.

P medicines can be bought only from a pharmacy in a pharmacist's presence. GSL medicines can be sold in other retail outlets. A POM-to-P change therefore does not permit unrestricted supermarket sale.

MHRA's prescription criteria include danger without medical supervision, even with correct use, and dangerous frequent misuse. They also cover a need for further investigation and normal parenteral administration. GSL classification requires that sale without pharmacist supervision is possible "with reasonable safety." These tests appear in the same MHRA guidance.

Reclassification can add restricted P or GSL availability while retaining prescription availability, or move all relevant packs. A simple case based on an eligible analogous product can use a type IB or type II analogous-product variation. Major applications include product information, a clinical overview and a risk-management plan. MHRA refers major cases to an expert committee, with downgrading where appropriate. MHRA's application guidance describes these routes. Public consultation applies to some reclassifications, not all.

EU classification depends on the authorisation

Articles 70 to 74a of Directive 2001/83/EC provide the EU classification framework. Article 71 sets prescription criteria: danger without supervision, widespread incorrect use that creates danger, substances that need further investigation, and normal parenteral administration. Article 72 defines nonprescription medicines by the absence of those criteria.

Authorities can consider dose, strength, pharmaceutical form, packaging and circumstances of use when waiving prescription criteria. Article 74 requires examination and appropriate amendment when new facts emerge. Article 74a can prevent authorities from relying, for one year, on significant preclinical tests or clinical trials that supported a same-substance classification change when another applicant seeks that change. That limit is not blanket market exclusivity for every switch. The legal assessment still concerns the proposed product conditions, rather than the substance name alone.

The procedure depends on the authorisation. Regulation 1234/2008 distinguishes mutual-recognition/decentralised, purely national and centrally authorised products. That framework does not make all switches national decisions or put them all under EMA.

For centrally authorised products, EMA evaluates and the European Commission grants the authorisation. Regulation 726/2004, Articles 9 and 10, separates the CHMP opinion from the Commission decision. An EMA opinion should not be treated as the final authorisation decision. Establish the authorisation route before developing the filing plan.

FDA Rx to OTC switch list examples

FDA's prescription-to-nonprescription list, updated June 16, 2026, includes the products below. The dates are US approval dates, not retail-launch dates.

FDA says Nexium 24 HR's conditions of use had not previously been marketed under an approved prescription NDA. Inclusion on its list does not make Nexium 24 HR an unqualified example of a true switch. Check each listed product and its footnotes before drawing conclusions about another strength, indication or market.

RegAffairs AI's answer on prescription-to-OTC switching covers the FDA and European routes.